Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Current Oncology · 15.02.2023 · 30 (2) · 2322-2347
DOI: 10.3390/curroncol30020179 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 15.02.2023. Verfasst von Parva Bhatt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Tufts University Medical Center, Boston, MA 02145, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Multiple myeloma remains an incurable disease with the usual disease course requiring induction therapy, autologous stem cell transplantation for eligible patients, and long-term maintenance. Risk stratification tools and cytogenetic alterations help inform individualized therapeutic choices for patients in hopes of achieving long-term remissions with preserved quality of life. Unfortunately, relapses occur at different stages of the course of the disease owing to the biological heterogeneity of the disease. Addressing relapse can be complex and challenging as there are both therapy- and patient-related factors to consider. In this broad scoping review of available therapies in relapsed/refractory multiple myeloma (RRMM), we cover the pharmacologic mechanisms underlying active therapies such as immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), monoclonal antibodies (mAbs), traditional chemotherapy, and Venetoclax. We then review the clinical data supporting the use of these therapies, organized based on drug resistance/refractoriness, and the role of autologous stem cell transplant (ASCT). Approaches to special situations during relapse such as renal impairment and extramedullary disease are also covered. Lastly, we look towards the future by briefly reviewing the clinical data supporting the use of chimeric antigen receptor (CAR-T) therapy, bispecific T cell engagers (BITE), and Cereblon E3 Ligase Modulators (CELMoDs).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tufts University Medical Center, Boston, MA 02145, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Bhatt, P., Kloock, C., & Comenzo, R. (2023). Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Current Oncology, 30(2), 2322-2347. https://doi.org/10.3390/curroncol30020179
Vancouver
Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Current Oncology. 2023;30(2):2322-2347. doi:10.3390/curroncol30020179
BibTeX
@article{Bhatt2023,
author = {Bhatt, Parva and Kloock, Colin and Comenzo, Raymond},
title = {Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {2},
pages = {2322--2347},
doi = {10.3390/curroncol30020179}
}
EUVIMED